Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs
- 17 May 2011
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 7 (8), 967-988
- https://doi.org/10.1517/17425255.2011.585969
Abstract
Large inter-individual and inter-ethnic differences are observed in efficacies and toxicities of medical drugs. To improve the predictability of these differences, pharmacogenetic information has been applied to clinical situations. Expanding pharmacogenetic information would be a valuable tool to the medical community as well as the patient to fulfill the promise of personalized anticancer drug therapy. This review highlights genetic polymorphisms and ethnic differences of genes, UGT1As, CYP3A4, CES1As, ABCB1, ABCC2, ABCG2, SLCO1B1, CDA and CYP2D6, involved in metabolism and disposition of three anticancer drugs: irinotecan, gemcitabine and tamoxifen. Recent pharmacogenetic studies have successfully identified distinct ethnic differences in genetic polymorphisms that are potentially involved in efficacies and toxicities of anticancer drugs. This achievement has led to personalized irinotecan therapy, reflecting ethnic differences in UGT1A1 genotypes, and possible benefits of genetic testing have also been suggested for gemcitabine and tamoxifen therapy, which still requires further validation. The ultimate goal for patients is a high rate or even perfect prediction of efficacies and toxicities of anticancer drugs in each ethnic population. For this challenge, more clinical studies combined with comprehensive omics approaches are necessary to further advance the field.Keywords
This publication has 101 references indexed in Scilit:
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancerCancer, 2010
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyBritish Journal of Cancer, 2010
- Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patientsBritish Journal of Cancer, 2009
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortBreast Cancer Research and Treatment, 2009
- Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal DegradationsPharmaceutical Research, 2008
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group studyBritish Journal of Cancer, 2008
- Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?British Journal of Cancer, 2007
- Tamoxifen, hot flashes and recurrence in breast cancerBreast Cancer Research and Treatment, 2007